Exa AI vs Komodo Health AI

Free plan with 1,000 searches/month. Researcher $20/month (5,000 searches). Scale $50/month (20,000 searches). Enterprise custom.

Enterprise licensing to pharmaceutical companies, health systems, and payers. No public pricing. Contact for pricing.

Review Exa's privacy policy. Search queries are processed on Exa's servers.

Patient health data de-identified under HIPAA de-identification standards. Access requires data use agreements and IRB approval for research purposes. Review Komodo's data governance framework.

• ✓Neural search approach finds semantically relevant content that keyword search misses for complex queries
• ✓Contents API provides full-text extraction eliminating additional crawling in RAG pipelines
• ✓Highlights extraction provides targeted relevant passages reducing token usage in RAG context
• ✓Competitive alternative to Tavily for AI application web search with different underlying approach

• ✓330 million patient longitudinal data coverage is one of the most comprehensive US real-world health datasets
• ✓Integrated claims, lab, and EHR data provides richer patient journey evidence than single-source datasets
• ✓Pulse SaaS interface makes real-world evidence accessible without custom database development
• ✓Pharmaceutical market access teams can generate regulatory-grade evidence from real-world data

• ✕Pricing scales quickly for production applications above the free tier
• ✕Search coverage may miss some niche or recent content compared to Google's comprehensive index
• ✕Neural search can return semantically related but not the most current results for rapidly developing topics

• ✕Enterprise-only licensing appropriate for pharmaceutical companies and large health systems with analytics budgets
• ✕Real-world data has limitations — claims-based patient identification is less accurate than clinical data
• ✕Regulatory acceptance of real-world evidence varies by market and indication — not a substitute for clinical trials